Case Study
ZoomDetails

Scaling Up Pluripotent Stem Cell-Based Therapies: Considerations, Current Challenges & Emerging Technologies

Allogeneic Cell Sourcing, Cell Therapy Supply Chain

Explore the latest advancements in scaling up induced pluripotent stem cell (iPSC)-based therapies. This comprehensive review delves into current technologies for iPSC expansion and differentiation, highlighting innovative strategies to overcome manufacturing challenges and accelerate the development of regenerative treatments. Read the full article in Cytotherapy: https://www.isct-cytotherapy.org/article/S1465-3249(25)00678-4/fulltext

Webinar
ZoomDetails

Understanding and leveraging cord blood bank capabilities and practices in cell therapy development

Allogeneic Cell Sourcing, Cell Collection Network, Clinical Trials Support, Industry Standardization

The cord blood banking industry has been around for over 30 years, focusing on acquiring units for use in hematopoietic stem cell transplant. Recent research indicates that cord blood can be a valuable source of naïve cells for cell therapy manufacturing. Cord blood banks are evolving their processes to accommodate the use of cord blood…

Webinar
ZoomDetails

Optimizing Access to High-Quality, Standardized and Compliant Leukopaks for the Development and Commercialization of Allogeneic Therapies

Allogeneic Cell Sourcing, Cell Collection Network, Clinical Trials Support, Industry Standardization

Cellular starting material is the most critical component in the allogeneic cell therapy manufacturing process. Ensuring material access while maintaining quality, consistency and regulatory compliance are necessary throughout every stage of clinical development through commercialization. During this webinar, you will learn about: Factors to ensure streamlined access to high-quality, consistent starting material for allogeneic therapies…

Case Study
ZoomDetails

How Cell Therapy Clinical Trials Can Save Time and Cost

Allogeneic Cell Sourcing, Clinical Trials Support

A client initiated a Phase I clinical trial for its allogeneic cell therapy. Several months in, limited success recruiting patients had led to an expensive lack of progress. The client engaged with the CIBMTR® Bioinformatics Consulting team through NMDP BioTherapies℠ to identify U.S. states and counties with the highest density of patients and donors with…

Webinar
ZoomDetails

Leveraging the Experience of Cord Blood Banking in Development of Cellular Therapies

Allogeneic Cell Sourcing

Along with gaining insights into how to tap into the expertise of cord blood banks and access therapy-matched cord blood units (CBUs), you’ll get a better understanding of: Comprehensive benefits of cords as an allogeneic cell source for cellular therapy Characteristics and attributes of the existing CBU inventory Importance of managing logistics for delivery of…

Webinar
ZoomDetails

Understanding Donor Characteristics to Improve Allogeneic Cell Therapy Outcomes for All

Allogeneic Cell Sourcing

Can donor-reported characteristics, like race and ethnicity, impact data quality for allogeneic cell therapies? That’s one of the questions our expert panelists will discuss during our upcoming webinar. You’ll walk away with a better understanding of:  Efficiencies in donor selection to reduce uncertainties about HLA matching and improve allogeneic cell therapy outcomes  HLA complexity in cell source selection …

Webinar
ZoomDetails

Navigating Scalability and Consistency in the Allogeneic Supply Chain

Allogeneic Cell Sourcing

In this webinar, we focus on the scalability of donor starting material to support the growth and commercialization of allogeneic therapies. Throughout this discussion, we answer these questions on scalability and consistency in the allogeneic supply chain: What are the major gaps currently in the industry? How can we gain a better understanding of what…

Webinar
ZoomDetails

International Differences in Cellular Starting Material Quality and Regulatory Requirements

Allogeneic Cell Sourcing

Navigating international differences in regulations for cellular starting material is complex. This is particularly true because the rapid advancement of the industry sometimes precedes regulatory guidance. When you’re procuring cellular starting material or distributing a cell or gene therapy product across international borders, you must consider the country or regional requirements at play and where…